Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127132 | 0.84 | CHRNB2 (0.41) | HTR3AHTR4MAPK1CHRNB2CHRNA4 | |
| SCHEMBL9265487 | 0.84 | CHRNB2 (0.41) | HTR3AHTR4MAPK1CHRNB2CHRNA4 | |
| SCHEMBL21815413 | 0.84 | CHRNB2 (0.41) | HTR3AHTR4MAPK1CHRNB2CHRNA4 | |
| SCHEMBL8741015 | 0.84 | CHRNB2 (0.41) | HTR3AHTR4MAPK1CHRNB2CHRNA4 | |
| SCHEMBL8740985 | 0.84 | CHRNB2 (0.41) | HTR3AHTR4MAPK1CHRNB2CHRNA4 | |
| SCHEMBL8741013 | 0.84 | CHRNB2 (0.41) | HTR3AHTR4MAPK1CHRNB2CHRNA4 | |
| SCHEMBL21589214 | 0.82 | GAA (0.40) | HTR3AHTR4 | |
| SCHEMBL21585804 | 0.82 | GAA (0.40) | HTR3AHTR4 | |
| SCHEMBL6213009 | 0.82 | GAA (0.40) | HTR3AHTR4 | |
| SCHEMBL6210320 | 0.82 | GAA (0.40) | HTR3AHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112204028-B | tetrahydro-1H-pyrazino [2,1-a ] isoindoloquinoline compounds for use in the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-12-29 | — | — | CN | disclosed |